---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-22-000002"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2022-01-31T23:59:59+00:00"
generated_at: "2026-06-27T13:37:14.278260+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics appoints Christopher Rovaldi as COO effective Feb 1, 2022

## Summary
- Christopher Rovaldi appointed Chief Operating Officer, effective February 1, 2022.
- Rovaldi brings 20+ years experience, most recently as consultant and president of NS Biopharma Consulting.
- Previously held senior roles at Acceleron Pharma (2007-2018), including SVP Program Management and Operations.
- Initial annual base salary of $470,000; target bonus 50% of salary; option to purchase 100,000 shares.
- Severance includes 9-12 months base salary and COBRA, with equity acceleration upon change of control termination.

## SEC filing metadata
- accession: 0001664710-22-000002
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2022-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/0001664710-22-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/kros-20220128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-22-000002
- JSON: https://secwatch.observer/filing/0001664710-22-000002.json
- Plain text: https://secwatch.observer/filing/0001664710-22-000002.txt

## Key facts
- Executive change
  Christopher Rovaldi was appointed as Chief Operating Officer at Keros Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: Christopher Rovaldi has been appointed to serve as the Company’s Chief Operating Officer, effective as of February 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/0001664710-22-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.